Halozyme Therapeutics Logo
US40637H1095
A0DLHS
HALO

Halozyme Therapeutics

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 100,52 € (+9,77 %). Medianen er 99,46 € (+8,62 %).

Køb
  16
Behold
  10
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Halozyme achieves over 60% EBITDA margin with lucrative licensing business

    Halozyme operates as a highly profitable licensing company that simplifies infusion therapies and, thanks to a licensing model and a high EBITDA margin, generates reliable cash flows. New self‑administration drug technologies and an extensive partner pipeline support further growth, especially amid the trend toward outpatient cancer therapies. As a result, Halozyme presents itself less as a speculative drug developer and more as a cash‑flow‑strong biotech investment. » Mere på finanzen.net


  • Halozyme presents tiered licensing growth strategy and strong Q2 results

    At the Morgan Stanley Healthcare Conference, Halozyme highlighted record revenue of $308 million for Q2 2024 and accelerated growth in partner products. The company emphasized the diversification of its technologies (ENHANZE, Hypercon, Surf Bio), five new business partnerships in 2024, and optimistic revenue guidance for 2024 as well as long‑term targets through 2028. Management views political risks and tariffs as having little impact, expects further contract signings, and is relying on AI‑driven efficiency, buybacks and selective M&A to strengthen the licensing base. » Mere på de.investing.com


  • Halozyme sees growth from subcutaneous delivery

    Halozyme reported strong growth at the Wells Fargo Healthcare Conference: revenue in Q2 2024 rose to $481m (+48%) and licensing income exceeded $300m (+50%). The ENHANZE platform is driving commercial switches to subcutaneous formats, and the company is expanding its pipeline with HyperCon, autoinjector technologies and several new partnerships. Management cites patent protection issues, a pending lawsuit with Merck and potential future declines in license royalties as risks, but emphasizes strong free cash flow, room for investment, share buybacks and debt reduction. » Mere på de.investing.com


  • Halozyme Therapeutics hits new all-time high at $109.69

    Halozyme Therapeutics' stock rose to a record high of $109.69, bringing market capitalization to about $12.4 billion. The shares are up 46.06% over the past 12 months, 54% over the past six months and 60% year-to-date. In the second quarter Halozyme beat expectations with a non-GAAP EPS of $2.28 (expectation $1.81) and revenue of $481 million (expectation $401.27 million), driven by record licensing revenues, after which the full-year guidance was raised. Analysts reacted positively: Citizens slightly raised its price target to $93 with a "market outperform" rating, and H.C. Wainwright reaffirmed "buy" with a $115 target following positive partner data. » Mere på de.investing.com


  • Halozyme hits record high of $109.59 after strong quarterly results

    Halozyme's stock climbed to an all-time high of $109.59 and is up about 62% year-to-date. In the second quarter the company beat expectations with non-GAAP earnings of $2.28 per share (expectation $1.81) and revenue of $481 million (forecast $401.27 million). Halozyme raised its full-year guidance, attributing the revision to record licensing revenue and robust growth in partner drugs. Several analysts raised estimates or price targets, and one analysis still sees the stock trading below its fair value despite the rally. » Mere på de.investing.com

I 2022 har Halozyme Therapeutics allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde Halozyme Therapeutics en omsætning på 435,22 mio. € og et nettoresultat på 218,11 mio. €
(EUR) september 2026
YoY
Omsætning 435,22 mio. 44,17 %
Bruttofortjeneste 362,41 mio. 42,23 %
Nettoresultat 218,11 mio. 46,07 %
EBITDA 292,11 mio. 40,68 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
10,43 mia. €
Antal aktier
114,01 mio.
Højeste/laveste i 52 uger
121,72 € - 55,62 €
Udbytte Nej
Beta
0,90
P/E (PE Ratio)
23,97
PEG (PEG Ratio)
-1,70
K/I (PB Ratio)
-207,39
P/S (PS Ratio)
6,37

Virksomhedsprofil

Halozyme Therapeutics, Inc. er en biofarmaceutisk teknologiplatformsvirksomhed med aktivitet i USA, Schweiz, Irland, Belgien, Japan og internationalt. Virksomhedens produkter er baseret på ENHANZE-lægemiddelleveringsteknologien, et patenteret rekombinant humant hyaluronidaseenzym (rHuPH20), som muliggør subkutan levering af injicerbare biologiske lægemidler, såsom monoklonale antistoffer og andre terapeutiske molekyler, samt små molekyler og væsker. Virksomhedens flagskibsprodukt er Hylenex recombinant, en formulering af rHuPH20, der anvendes til subkutan væskeadministration for at opnå hydrering, forbedre spredningen og optagelsen af andre injicerede lægemidler ved subkutan urografi og forbedre resorptionen af røntgenkontrastmidler. Virksomheden udvikler også Perjeta; RITUXAN HYCELA og MabThera SC til behandling af non-Hodgkin-lymfom og kronisk lymfatisk leukæmi (CLL); RITUXAN SC til patienter med CLL; og HYQVIA til behandling af immundefektsygdomme. Derudover udvikler den Tecentriq til ikke-småcellet lungekræft; OCREVUS til multipel sklerose; DARZALEX til behandling af patienter med amyloidose, smoldrende myelom og multipelt myelom; nivolumab til behandling af solide tumorer; ARGX-113, en human neonatal Fc-receptor; ARGX-117 til behandling af autoimmune sygdomme; og BMS-986179, et anti-CD-73-antistof. Virksomheden har samarbejder med F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; og ViiV Healthcare Limited om små og store molekylemål til behandling og forebyggelse af hiv. Halozyme Therapeutics, Inc. blev grundlagt i 1998 og har hovedsæde i San Diego, Californien.

Navn
Halozyme Therapeutics
CEO
Helen I. Torley
Hjemsted San Diego, ca
USA
Websted
Sektor
Sundhed
Branche
Bioteknologi
Børsnotering
03.10.2008
Medarbejdere 423

Tickersymboler

Børs Symbol
NASDAQ
HALO
London Stock Exchange
0J2O.L
Frankfurt
RV7.F
Düsseldorf
RV7.DU
London
0J2O.L
SIX
RV7.SW
München
RV7.MU
🍪

Parqet  bruger cookies. Læs mere